Clinical Trials Logo
  1. Home
  2. Age-Related Maculopathy
  3. NCT00474695

Study Evaluating Genotypes Using Lucentis — SEAGUL  

Age-Related Maculopathy Clinical Trial

Official title:
VEGF and HTRA1 DNA Polymorphisms in Neovascular AMD Pathogenesis and Response to Lucentis

Clinical Trial Summary

The purpose of the study is to investigate whether the efficacy of Lucentis treatment for exudative age-related macular degeneration is associated with VEGF and HTRA1 DNA polymorphisms

Clinical Trial Description

Treatment naive exudative AMD patients will receive Lucentis treatment as standard of care, and followed monthly for 12 months. Standard ophthalmologic exams will be performed, along with ETDRS visual acuity and optical coherence tomography (OCT). A blood sample will be obtained for DNA analysis. The primary outcome measure is change in visual acuity at 4 months after initial Lucentis treatment. Secondary outcomes are change in visual acuity and retinal thickness at 12 months. ;

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00474695
Study type Observational
Source University of Utah
Contact
Status Terminated
Phase N/A
Start date May 2007
Completion date December 2009
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT01115387 - GARM II: A Study on the Genetics of Age-related Maculopathy
Completed NCT00775411 - Safety and Efficacy of a New Therapy as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) in Subjects With Wet Age-Related Macular Degeneration (AMD) Phase 2
Completed NCT00511706 - Safety and Efficacy of a New Treatment as Adjunctive Therapy to Anti-vascular Endothelial Growth Factor (Anti-VEGF) Treatment in Patients With Age-Related Macular Degeneration (AMD) Phase 2
Completed NCT00473642 - Reduced Fluence Photodynamic Therapy (PDT) With Visudyne in Combination With Lucentis for Age-Related Macular Degeneration Phase 4
Completed NCT00759044 - Validation of a New Methodology for Mapping the Human Blood-Retinal Barrier Function N/A
Completed NCT00056823 - Intravitreal Injections of rhuFab V2 in Combination With Visudyne in Subjects With Age Related Macular Degeneration (AMD) Phase 1/Phase 2
Recruiting NCT05752045 - OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases N/A
Completed NCT00051129 - Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) Phase 3
Suspended NCT00460967 - Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis Phase 3
Completed NCT01024998 - Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD) Phase 1
Completed NCT01494805 - Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration Phase 1/Phase 2
Completed NCT01003691 - Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy Phase 1
Terminated NCT01577381 - Efficacy, Safety And Tolerability Study Of RN6G In Subjects With Geographic Atrophy Secondary to Age-related Macular Degeneration Phase 2
Terminated NCT01122511 - Safety and Efficacy of Dexamethasone as Adjunctive Therapy to Ranibizumab in Subjects With Choroidal Neovascularization and Age-Related Macular Degeneration Phase 2
Completed NCT00877032 - Safety And Tolerability Study Of RN6G In Patients With Dry, Age-Related Macular Degeneration Phase 1